Kiniksa Pharmaceuticals International, plc (KNSA) stock
KNSANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 27, 2026Score 14/30481% above fair value
$93.89+0.36 (+0.38%)
Close on Nov 20, 2026Market cap $14.76BP/E 72.2Yield –
Kiniksa Pharmaceuticals International shares outstanding
Diluted shares outstanding: the weighted share count used for earnings per share, adjusted for stock splits.
Kiniksa Pharmaceuticals International's shares outstanding was 85M at Sep 30, 2026. For fiscal 2025 it was 79M, up 10.6% from the year before. The highest annual figure on record is 79M in fiscal 2025.
Annual shares outstanding
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 79M | +10.6% |
| FY2024 | Dec 31, 2024 | 71M | -0.7% |
| FY2023 | Dec 31, 2023 | 72M | +2.1% |
| FY2022 | Dec 31, 2022 | 70M | +2.7% |
| FY2021 | Dec 31, 2021 | 69M | +10.9% |
| FY2020 | Dec 31, 2020 | 62M | +14.4% |
| FY2019 | Dec 31, 2019 | 54M | +82.9% |
| FY2018 | Dec 31, 2018 | 30M | +1532.7% |
| FY2017 | Dec 31, 2017 | 2M | – |
Quarterly shares outstanding
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | 85M | +6.1% |
| Q2 FY2026 | Jun 30, 2026 | 83M | +7.0% |
| Q1 FY2026 | Mar 31, 2026 | 82M | +8.2% |
| Q4 FY2025 | Dec 31, 2025 | 82M | +13.1% |
| Q3 FY2025 | Sep 30, 2025 | 80M | +11.6% |
| Q2 FY2025 | Jun 30, 2025 | 78M | +9.8% |
| Q1 FY2025 | Mar 31, 2025 | 76M | +7.8% |
| Q4 FY2024 | Dec 31, 2024 | 72M | -7.1% |
| Q3 FY2024 | Sep 30, 2024 | 72M | +2.2% |
| Q2 FY2024 | Jun 30, 2024 | 71M | -0.9% |
| Q1 FY2024 | Mar 31, 2024 | 71M | +1.3% |
| Q4 FY2023 | Dec 31, 2023 | 78M | +9.9% |
| Q3 FY2023 | Sep 30, 2023 | 70M | -0.5% |
| Q2 FY2023 | Jun 30, 2023 | 72M | +3.4% |
| Q1 FY2023 | Mar 31, 2023 | 70M | +0.9% |
| Q4 FY2022 | Dec 31, 2022 | 71M | +2.7% |
| Q3 FY2022 | Sep 30, 2022 | 71M | +2.8% |
| Q2 FY2022 | Jun 30, 2022 | 69M | +1.3% |
| Q1 FY2022 | Mar 31, 2022 | 69M | +1.3% |
| Q4 FY2021 | Dec 31, 2021 | 69M | +1.3% |
| Q3 FY2021 | Sep 30, 2021 | 69M | +4.1% |
| Q2 FY2021 | Jun 30, 2021 | 68M | +18.1% |
| Q1 FY2021 | Mar 31, 2021 | 68M | +23.4% |
| Q4 FY2020 | Dec 31, 2020 | 68M | +24.1% |
| Q3 FY2020 | Sep 30, 2020 | 66M | +20.3% |
| Q2 FY2020 | Jun 30, 2020 | 58M | +6.3% |
| Q1 FY2020 | Mar 31, 2020 | 55M | +6.9% |
| Q4 FY2019 | Dec 31, 2019 | 55M | +12.8% |
| Q3 FY2019 | Sep 30, 2019 | 55M | +13.8% |
| Q2 FY2019 | Jun 30, 2019 | 54M | +197.2% |
| Q1 FY2019 | Mar 31, 2019 | 52M | +1988.0% |
| Q4 FY2018 | Dec 31, 2018 | 49M | +2098.5% |
| Q3 FY2018 | Sep 30, 2018 | 48M | +2381.0% |
| Q2 FY2018 | Jun 30, 2018 | 18M | +995.2% |
| Q1 FY2018 | Mar 31, 2018 | 2M | – |
| Q4 FY2017 | Dec 31, 2017 | 2M | – |
| Q3 FY2017 | Sep 30, 2017 | 2M | – |
| Q2 FY2017 | Jun 30, 2017 | 2M | – |
See a number that looks wrong?